Zacks Investment Research upgraded shares of Phibro Animal Health (NASDAQ:PAHC) from a sell rating to a hold rating in a research note issued to investors on Monday morning.

According to Zacks, “Phibro ended  second-quarter fiscal 2018 on a mixed note, with bottom line exceeding the Zacks Consensus Estimate and revenues declining marginally on a year-over-year basis. Segment-wise, a persistent decline in Mineral Nutrition segment sales is likely to prove a drag. Customer consolidation can also adversely affect Phibro’s revenues. Moreover, headwinds such as unfavorable currency movement and tough competitive scenario continue to pose threats. Over the past three months, Phibro has been trading below the broader industry. However, on a positive note, Animal Health remained the key contributing business, delivering positive growth on a year-over-year basis. We are also encouraged by the expansion in the gross margin in the reported quarter.”

Other analysts have also recently issued research reports about the stock. Piper Jaffray Companies set a $41.00 price target on shares of Phibro Animal Health and gave the stock a buy rating in a research note on Friday, October 6th. BidaskClub upgraded shares of Phibro Animal Health from a strong sell rating to a sell rating in a research note on Saturday, January 6th. Finally, ValuEngine cut shares of Phibro Animal Health from a buy rating to a hold rating in a research note on Thursday, November 9th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. Phibro Animal Health presently has a consensus rating of Hold and a consensus price target of $38.25.

Phibro Animal Health (NASDAQ PAHC) traded down $0.15 during midday trading on Monday, hitting $35.70. 43,051 shares of the company were exchanged, compared to its average volume of 79,906. The company has a debt-to-equity ratio of 1.91, a current ratio of 3.26 and a quick ratio of 1.85. The stock has a market cap of $1,430.00, a P/E ratio of 21.00, a price-to-earnings-growth ratio of 4.12 and a beta of 1.27. Phibro Animal Health has a 1 year low of $26.10 and a 1 year high of $40.25.

Phibro Animal Health (NASDAQ:PAHC) last posted its earnings results on Monday, November 6th. The company reported $0.38 EPS for the quarter, beating the Zacks’ consensus estimate of $0.37 by $0.01. The firm had revenue of $193.40 million for the quarter, compared to the consensus estimate of $189.89 million. Phibro Animal Health had a net margin of 8.22% and a return on equity of 39.76%. The company’s revenue was up 2.9% on a year-over-year basis. During the same period last year, the firm posted $0.36 EPS. equities analysts expect that Phibro Animal Health will post 1.57 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Wednesday, December 27th. Investors of record on Wednesday, December 6th were paid a dividend of $0.10 per share. This represents a $0.40 dividend on an annualized basis and a yield of 1.12%. The ex-dividend date was Tuesday, December 5th. Phibro Animal Health’s dividend payout ratio is currently 23.53%.

A number of large investors have recently modified their holdings of PAHC. KBC Group NV acquired a new stake in Phibro Animal Health during the 2nd quarter worth $166,000. Victory Capital Management Inc. boosted its stake in Phibro Animal Health by 17.6% during the 2nd quarter. Victory Capital Management Inc. now owns 5,380 shares of the company’s stock worth $199,000 after purchasing an additional 807 shares during the period. Capital Fund Management S.A. acquired a new stake in Phibro Animal Health during the 2nd quarter worth $210,000. Susquehanna International Group LLP acquired a new stake in Phibro Animal Health during the 2nd quarter worth $219,000. Finally, BNP Paribas Arbitrage SA boosted its stake in Phibro Animal Health by 55.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 5,933 shares of the company’s stock worth $220,000 after purchasing an additional 2,123 shares during the period. Hedge funds and other institutional investors own 48.42% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Phibro Animal Health (PAHC) Raised to “Hold” at Zacks Investment Research” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.dailypolitical.com/2018/01/12/phibro-animal-health-pahc-raised-to-hold-at-zacks-investment-research.html.

About Phibro Animal Health

Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products.

Get a free copy of the Zacks research report on Phibro Animal Health (PAHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.